Loading...
•
Dec 31, 2020
Paysign Q4 2020 Earnings Report
Reported financial results for the fourth-quarter and fiscal year 2020.
Key Takeaways
Paysign's Q4 2020 results were impacted by the COVID-19 pandemic, particularly affecting clients in the pharma and plasma industries. The company added 55 new plasma programs and experienced a net growth in card programs of 61. Paysign remains well-capitalized with $7.8 million of unrestricted cash and zero debt.
COVID-19 pandemic negatively impacted clients in the pharma and plasma industries.
The month of May marked the low point for the plasma business, with improvements seen throughout the year.
55 new plasma programs were added, and there was a net growth in card programs of 61.
The company remains well-capitalized with $7.8 million of unrestricted cash and zero debt.
Paysign
Paysign
Forward Guidance
Paysign anticipates that COVID-19 and government stimulus measures will likely continue to impact its business into 2021. The company remains cautiously optimistic that its businesses will continue to rebound as vaccinations become more prevalent and business restrictions are lifted.
Positive Outlook
- Optimistic outlook in the recovery of the pharma and plasma industries.
- Company's ability to return to year-over-year growth.
- Company remains well-capitalized and positioned to weather impacts from the pandemic.
- Expects an upturn in the second half of 2021 resulting from vaccinations becoming more prevalent
- Expects an upturn in the second half of 2021 resulting from business restrictions being lifted.
Challenges Ahead
- The pandemic continues to have a meaningful impact on the company’s business and operations
- Inability to continue current growth rate in future periods.
- Downturn in the economy, including as a result of COVID-19, as well as government stimulus measures, could reduce customer base and demand for products and services.
- Operating in a highly regulated environment
- Failure by us or business partners to comply with applicable laws and regulations